Evolutionary alteration of ALOX15 specificity optimizes the biosynthesis of antiinflammatory and proresolving lipoxins

Edited by Klaus van Leyen, Harvard Medical School, Charlestown, MA, and accepted by Editorial Board Member Ruslan Medzhitov May 27, 2016 (received for review March 10, 2016)

Online Impact

vol. 113 no. 30 E4266-E4275

DOI:

PubMed:

Published By:

Print ISSN:

Online ISSN:

History:

^aInstitute of Biochemistry, University Medicine Berlin–Charité, D-10117 Berlin, Germany;
^bDepartament de Química, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain;
^cInstitut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain;
^dDepartment of Cell and Molecular Biology of Drugs, Faculty of Pharmacy, Comenius University, 832 32 Bratislava, Slovakia

Edited by Klaus van Leyen, Harvard Medical School, Charlestown, MA, and accepted by Editorial Board Member Ruslan Medzhitov May 27, 2016 (received for review March 10, 2016)

↵¹S.A. and F.K. contributed equally to this work.
↵²Present address: Institute of Biotechnology, RWTH Aachen University, 52074 Aachen, Germany.
↵³To whom correspondence should be addressed. Email: hartmut.kuehn{at}charite.de.

Author contributions: S.A., F.K., T.H., H.K., and D.H. designed research; S.A., F.K., À.G.-L., M.P., P.S., L.M., J.M.L., S.S., H.K., and D.H. performed research; S.A., F.K., À.G.-L., M.P., P.S., L.M., J.M.L., S.S., H.K., and D.H. analyzed data; and S.A., À.G.-L., T.H., H.K., and D.H. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. K.v.L. is a guest editor invited by the Editorial Board.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1604029113/-/DCSupplemental.